Extending survival for people with hepatitis C using tobacco dependence treatment

Coral Gartner, Alleshia Miller, Billie Bonevski

Research output: Contribution to journalLetterpeer-review

7 Citations (Scopus)


The availability of direct-acting antiviral (DAA) therapies for hepatitis C virus (HCV) has led WHO to advocate for the elimination of HCV. However, a 2017 Cochrane review1 suggests that DAA treatment might not improve morbidity and mortality in people living with HCV: trials have shown no benefit on these endpoints, despite a sustained virological response. Stefan Wiktor and John Scott (July 8, p 107)2 state that longer term observational data are needed to assess mortality in people receiving DAA treatment for HCV.
Original languageEnglish
Pages (from-to)2033
Number of pages1
JournalThe Lancet
Issue number10107
Publication statusPublished - 4 Nov 2017
Externally publishedYes


  • hepatitis C
  • tobacco dependence
  • HIV
  • HCV
  • direct-acting antiviral
  • DAA
  • treatment
  • virological


Dive into the research topics of 'Extending survival for people with hepatitis C using tobacco dependence treatment'. Together they form a unique fingerprint.

Cite this